SI-BONE (SIBN) Stock Price

SI-BONE Price

NASDAQ·CLOSED
18.03USD-0.21 (-1.16 %)
Market closed

Revenue has compounded at 13.9% per year over the past 13 years to 200.93 M USD. SI-BONE's net margin stands at -9.4%, up from -62.8% several years earlier. Analysts set a median price target of 25.50 USD, implying 41.4% above the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 55% above its 52-week low.

SI-BONE stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of SI-BONE over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SI-BONE stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SI-BONE's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

SI-BONE Stock Price History
DateSI-BONE Price
8/5/202618.03 USD
8/4/202618.24 USD
8/3/202618.45 USD
7/31/202617.76 USD
7/30/202617.99 USD
7/29/202618.17 USD
7/27/202617.18 USD
7/23/202616.47 USD
7/22/202616.71 USD
7/21/202617.04 USD
7/20/202617.12 USD
7/17/202617.38 USD
7/16/202617.72 USD
7/15/202617.25 USD
7/14/202616.91 USD
7/13/202617.98 USD
7/10/202617.56 USD
7/9/202617.42 USD
7/8/202616.94 USD
7/7/202617.30 USD
7/6/202616.94 USD
7/2/202617.11 USD
7/1/202616.80 USD
6/30/202616.32 USD
6/29/202616.88 USD
6/26/202617.33 USD
6/25/202616.76 USD
6/24/202616.34 USD
6/23/202615.95 USD
6/22/202616.05 USD
6/18/202615.73 USD
6/17/202615.91 USD
6/16/202615.28 USD
6/15/202615.40 USD
6/12/202615.36 USD
6/11/202615.27 USD
6/10/202615.70 USD
6/9/202615.53 USD
6/8/202614.97 USD
6/5/202615.08 USD
6/4/202614.60 USD
6/3/202613.74 USD
6/2/202613.88 USD
6/1/202614.13 USD
5/29/202614.29 USD
5/28/202614.50 USD
5/27/202614.16 USD
5/26/202614.57 USD
5/22/202614.55 USD
5/21/202614.76 USD
5/20/202614.73 USD
5/19/202614.84 USD
5/18/202614.76 USD
5/15/202614.16 USD
5/14/202614.60 USD
5/13/202614.16 USD
5/12/202613.90 USD
5/11/202611.61 USD
5/8/202612.27 USD
5/7/202612.95 USD
5/6/202612.99 USD
5/5/202613.55 USD
5/4/202613.35 USD
5/1/202613.21 USD
4/30/202612.39 USD
4/29/202611.93 USD
4/28/202612.36 USD
4/27/202613.15 USD
4/24/202613.52 USD
4/23/202613.40 USD
4/22/202613.87 USD
4/21/202613.82 USD
4/20/202614.32 USD
4/17/202614.09 USD
4/16/202613.67 USD
4/15/202614.49 USD
4/14/202614.43 USD
4/13/202614.00 USD
4/10/202612.84 USD
4/9/202613.69 USD
4/8/202613.93 USD
4/7/202613.17 USD
4/6/202613.21 USD
4/2/202613.12 USD
4/1/202613.01 USD
3/31/202612.63 USD
3/30/202612.28 USD
3/27/202612.29 USD
3/26/202612.84 USD
3/25/202612.91 USD
3/24/202613.17 USD
3/23/202612.99 USD
3/20/202612.79 USD
3/19/202612.77 USD
3/18/202612.85 USD
3/17/202612.84 USD
3/16/202612.87 USD
3/13/202613.05 USD
3/12/202613.82 USD
3/11/202614.05 USD
3/10/202613.82 USD
3/9/202614.03 USD
3/6/202613.83 USD
3/5/202614.07 USD
3/4/202614.71 USD
3/3/202615.34 USD
3/2/202615.70 USD
2/27/202615.52 USD
2/26/202616.23 USD
2/25/202615.80 USD
2/24/202615.29 USD
2/23/202615.62 USD
2/20/202615.48 USD
2/19/202615.47 USD
2/18/202615.74 USD
2/17/202615.25 USD
2/13/202615.33 USD
2/12/202614.98 USD
2/11/202615.24 USD
2/10/202615.40 USD
2/9/202615.39 USD
2/6/202615.59 USD
2/5/202615.72 USD
2/4/202615.83 USD
2/3/202616.26 USD
2/2/202616.37 USD
1/30/202616.58 USD
1/29/202616.55 USD
1/28/202616.74 USD
1/27/202617.03 USD
1/26/202617.14 USD
1/23/202616.80 USD
1/22/202616.92 USD
1/21/202616.98 USD
1/20/202616.93 USD
1/16/202617.00 USD
1/15/202617.58 USD
1/14/202617.44 USD
1/13/202617.88 USD
1/12/202617.87 USD
1/9/202620.44 USD
1/8/202620.88 USD
1/7/202621.40 USD
1/6/202620.40 USD
1/5/202619.97 USD
1/2/202619.79 USD
12/31/202519.72 USD
12/30/202519.70 USD
12/29/202520.17 USD
12/26/202520.36 USD
12/24/202520.36 USD
12/23/202520.39 USD
12/22/202520.81 USD
12/19/202520.38 USD
12/18/202520.25 USD
12/17/202519.14 USD
12/16/202519.42 USD
12/15/202518.41 USD
12/12/202518.59 USD
12/11/202518.82 USD
12/10/202518.79 USD
12/9/202519.00 USD
12/8/202519.00 USD
12/5/202519.68 USD
12/4/202519.24 USD
12/3/202519.18 USD
12/2/202519.42 USD
12/1/202518.87 USD
11/28/202519.46 USD
11/26/202519.48 USD
11/25/202519.67 USD
11/24/202519.49 USD
11/21/202519.50 USD
11/20/202518.68 USD
11/19/202518.60 USD
11/18/202518.36 USD
11/17/202517.92 USD
11/14/202517.42 USD
11/13/202517.26 USD
11/12/202518.00 USD
11/11/202518.22 USD
11/10/202515.68 USD
11/7/202515.77 USD
11/6/202515.19 USD
11/5/202515.36 USD
11/4/202515.35 USD
11/3/202515.05 USD
10/31/202514.83 USD
10/30/202515.15 USD
10/29/202515.26 USD
10/28/202515.79 USD
10/27/202515.66 USD
10/24/202515.49 USD
10/23/202515.43 USD
10/22/202515.40 USD
10/21/202515.52 USD
10/20/202515.22 USD
10/17/202514.74 USD
10/16/202515.10 USD
10/15/202515.22 USD
10/14/202515.26 USD
10/13/202514.94 USD
10/10/202514.78 USD
10/9/202515.72 USD
10/8/202515.21 USD
10/7/202515.33 USD
10/6/202514.49 USD
10/3/202514.50 USD
10/2/202514.31 USD
10/1/202514.27 USD
9/30/202514.72 USD
9/29/202514.17 USD
9/26/202514.05 USD
9/25/202514.14 USD
9/24/202514.22 USD
9/23/202514.26 USD
9/22/202514.84 USD
9/19/202514.60 USD
9/18/202515.18 USD
9/17/202514.71 USD
9/16/202515.10 USD
9/15/202515.14 USD
9/12/202515.70 USD
9/11/202516.32 USD
9/10/202515.66 USD
9/9/202516.04 USD
9/8/202516.13 USD
9/5/202516.29 USD
9/4/202516.35 USD
9/3/202516.22 USD
9/2/202516.45 USD
8/29/202516.67 USD
8/28/202516.62 USD
8/27/202516.59 USD
8/26/202516.42 USD
8/25/202516.05 USD
8/22/202516.39 USD
8/21/202515.64 USD
8/20/202515.54 USD
8/19/202515.49 USD
8/18/202515.54 USD
8/15/202515.46 USD
8/14/202515.30 USD
8/13/202515.70 USD
8/12/202515.20 USD
8/11/202515.40 USD
8/8/202515.68 USD
8/7/202516.32 USD
Access this data via the Eulerpool API
Get Free API Key

SI-BONE Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
138.89 M USD
-46.93 M USD
-43.34 M USD
Jan 1, 2024
167.18 M USD
-35.25 M USD
-30.91 M USD
Jan 1, 2025
200.93 M USD
-22.33 M USD
-18.91 M USD
Jan 1, 2026 (e)
231.62 M USD
87.49 M USD
-19.21 M USD
Jan 1, 2027 (e)
266.61 M USD
100.70 M USD
-16.02 M USD
Jan 1, 2028 (e)
305.28 M USD
115.31 M USD
-10.38 M USD
Jan 1, 2029 (e)
350.20 M USD
132.28 M USD
2.21 M USD
Jan 1, 2030 (e)
400.10 M USD
151.12 M USD
14.13 M USD

SI-BONE Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 9:09 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
41.0042.0047.0055.0067.0073.0090.00106.00138.00167.00200.00231.00266.00305.00350.00400.00
2.502.4411.9017.0221.828.9623.2917.7830.1921.0119.7615.5015.1514.6614.7514.29
85.3785.7189.3690.9189.5587.6787.7884.9178.9979.0479.5079.5079.5079.5079.5079.50
35.0036.0042.0050.0060.0064.0079.0090.00109.00132.00159.00183.65211.47242.48278.25318.00
-26.00-17.00-17.00-13.00-36.00-38.00-53.00-59.00-46.00-35.00-22.0087.00100.00115.00132.00151.00
-63.41-40.48-36.17-23.64-53.73-52.05-58.89-55.66-33.33-20.96-11.0037.6637.5937.7037.7137.75
-28.00-20.00-23.00-17.00-38.00-43.00-56.00-61.00-43.00-30.00-18.00-19.00-16.00-10.002.0014.00
3.70-28.5715.00-26.09123.5313.1630.238.93-29.51-30.23-40.005.56-15.79-37.50-120.00600.00
2.923.2715.6920.5925.0331.7533.5634.5940.5841.9943.5143.5143.5143.5143.5143.51
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales SI-BONE generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SI-BONE retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SI-BONE's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares SI-BONE has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SI-BONE's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

SI-BONE stock margins

The SI-BONE margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SI-BONE. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SI-BONE.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
88.43 %
-58.85 %
-62.75 %
Jan 1, 2022
85.24 %
-56.14 %
-57.57 %
Jan 1, 2023
78.78 %
-33.79 %
-31.20 %
Jan 1, 2024
79.03 %
-21.08 %
-18.49 %
Jan 1, 2025
79.57 %
-11.11 %
-9.41 %
Jan 1, 2026 (e)
79.57 %
37.77 %
-8.29 %
Jan 1, 2027 (e)
79.57 %
37.77 %
-6.01 %
Jan 1, 2028 (e)
79.57 %
37.77 %
-3.40 %

SI-BONE Stock Revenue, EBIT, Earnings per Share

The SI-BONE earnings per share therefore indicates how much revenue SI-BONE has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.69 USD
-1.58 USD
-1.69 USD
Jan 1, 2022
3.08 USD
-1.73 USD
-1.77 USD
Jan 1, 2023
3.42 USD
-1.16 USD
-1.07 USD
Jan 1, 2024
3.98 USD
-0.84 USD
-0.74 USD
Jan 1, 2025
4.62 USD
-0.51 USD
-0.43 USD
Jan 1, 2026 (e)
5.24 USD
2.01 USD
-0.43 USD
Jan 1, 2027 (e)
6.04 USD
2.31 USD
-0.36 USD
Jan 1, 2028 (e)
6.91 USD
2.65 USD
-0.24 USD

SI-BONE business model & stock analysis

SI-BONE Inc. is an innovative medical technology company based in Santa Clara, California. It was founded in 2008 by a group of orthopedic surgeons, engineers, and entrepreneurs who aimed to improve the treatment of lower back pain. The company is now globally recognized and specializes in the development and marketing of implants for the treatment of pain and discomfort in the pelvic and back areas. SI-BONE focuses on the treatment of pain and discomfort in the pelvic and back areas, offering a range of products for this purpose. The company's main focus is on the development of innovative implants that can be used minimally invasively, with the goal of providing patients with quick recovery and improved quality of life. The flagship product of SI-BONE is the iFuse implant. This implant is used in patients with chronic lower back pain caused by instability of the spine or pelvis. The iFuse implant stabilizes the pelvis and thereby reduces the pain originating from the unstable joint region. The iFuse implant has been FDA approved and is now available in over 40 countries worldwide. In addition to the iFuse implant, SI-BONE also offers a variety of other products tailored to the needs of physicians and patients. These include implantable instruments and consumables such as bone screws or arthroscopy needles. SI-BONE is a publicly traded company listed on NASDAQ under the ticker symbol "SIBN." The company's business model is based on providing innovative products to physicians and hospitals that optimize the treatment of back pain. To achieve this, SI-BONE works closely with leading industry professionals to enable optimal treatment of back pain. SI-BONE has established itself as a strong, innovative company specializing in minimally invasive implants in the field of pain therapy. Through close collaboration with physicians and specialists and investment in research and development of cutting-edge technologies, SI-BONE aims to continue growing and achieve a leading position in the field of pain therapy.

SI-BONE SWOT Analysis

Strengths

SI-BONE Inc possesses advanced proprietary technology, allowing it to develop innovative medical solutions for patients suffering from various spinal disorders.

SI-BONE Inc has gained a strong reputation within the healthcare industry for its effective diagnostic and treatment solutions, resulting in increased trust from healthcare professionals and patients.

SI-BONE Inc has a substantial portfolio of intellectual property rights, including patents and trademarks, providing a competitive advantage and protecting its innovative technologies.

Weaknesses

SI-BONE Inc heavily relies on its primary product offerings, potentially exposing the company to market fluctuations and limited revenue streams.

Compared to some major competitors, SI-BONE Inc has a relatively smaller market presence, which may limit its ability to reach a wider customer base and compete for market share.

SI-BONE Inc's pricing structure may be perceived as higher compared to some alternatives in the market, potentially leading to pricing sensitivity among cost-conscious customers.

Opportunities

SI-BONE Inc can explore opportunities to expand its reach into untapped geographical markets, allowing the company to target a wider customer base and increase its revenue potential.

By continuously investing in research and development, SI-BONE Inc can introduce new products or enhancements to its existing product line, catering to evolving customer needs and expanding its market share.

SI-BONE Inc can establish strategic partnerships with other companies or healthcare organizations to leverage complementary expertise and resources, fueling growth and market penetration.

Threats

SI-BONE Inc operates in a highly competitive industry, facing competition from both established companies and emerging startups, which could impact its market share and profitability.

The medical industry is subject to stringent regulations and compliance requirements. SI-BONE Inc may face challenges related to regulatory approvals, affecting its ability to commercialize products in a timely manner.

Fluctuations in the global economy, changes in healthcare policies, or economic downturns can influence customer spending patterns, potentially impacting SI-BONE Inc's revenues and profitability.

SI-BONE Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

SI-BONE Employees
Details
Date
SI-BONE Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

SI-BONE Segments

SI-BONE Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Domestic
International
Details
Date
United States
Domestic
International
Jan 1, 2018
0.00 USD
50.14 M USD
5.24 M USD
Jan 1, 2019
61.84 M USD
0.00 USD
5.46 M USD
Jan 1, 2020
68.12 M USD
0.00 USD
5.27 M USD
Jan 1, 2021
82.74 M USD
0.00 USD
7.41 M USD
Jan 1, 2022
98.75 M USD
0.00 USD
7.66 M USD
Jan 1, 2023
130.62 M USD
0.00 USD
8.27 M USD
Jan 1, 2024
158.42 M USD
0.00 USD
8.76 M USD
Jan 1, 2025
191.08 M USD
0.00 USD
9.85 M USD

SI-BONE Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

SI-BONE historical P/E ratio, EBIT multiple, and P/S ratio

SI-BONE annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

SI-BONE shares outstanding

The number of shares of SI-BONE was 43.51 M in 2025. This indicates how many shares SI-BONE is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
33.56 M Stocks
Jan 1, 2022
34.59 M Stocks
Jan 1, 2023
40.58 M Stocks
Jan 1, 2024
41.99 M Stocks
Jan 1, 2025
43.51 M Stocks
Jan 1, 2026 (e)
43.51 M Stocks
Jan 1, 2027 (e)
43.51 M Stocks
Jan 1, 2028 (e)
43.51 M Stocks

Current SI-BONE forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
93.75 % (15)
Hold
6.25 % (1)
Sell
0.00 % (0)
12M Price Target
25.50
Last Price
18.03
Currency
USD
12M Return Potential
41.43 %
LTM Return
0 %

SI-BONE Analyst Rating Actions

DateFirmActionRatingReliability
7/16/2026
Truist Securities
Truist Securities
MaintainedBuy–
5/12/2026
Truist Securities
Truist Securities
MaintainedBuy–
5/12/2026
TD Cowen
TD Cowen
MaintainedBuy60
4/15/2026
Truist Securities
Truist Securities
MaintainedBuy–
2/24/2026
Truist Securities
Truist Securities
MaintainedBuy–
2/24/2026
TD Cowen
TD Cowen
MaintainedBuy60
12/18/2025
Truist Securities
Truist Securities
MaintainedBuy–
12/17/2025
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
12/16/2025
Needham
Needham
MaintainedBuy70
12/2/2025
Morgan Stanley
Morgan Stanley
MaintainedOverweight60

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

SI-BONE Earnings Calls

2025

SI-BONE Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.16USD-56.37 MUSD-2026 Q2
5/11/2026-0.19USD-52.13 MUSD-2026 Q1
2/23/2026-0.13USD-56.51 MUSD-2025 Q4
1/12/2026-0.11USD-66.24 MUSD-2026 Q4
11/12/2024-0.24USD-41.31 MUSD-2024 Q3
4/29/2024-0.27USD-38.40 MUSD-2024 Q1
2/26/2024-0.29USD-37.27 MUSD-2023 Q4
8/7/2023-0.43USD-30.98 MUSD-2023 Q2
5/8/2023-0.41USD-28.58 MUSD-2023 Q1
2/27/2023-0.41USD-30.50 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the SI-BONE stock

50/100
31
Environment
86
Social
32
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees43
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

SI-BONE shareholder structure

% Name
6.72321%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
6.59492%
Brown Advisory
Brown Advisory
5.83876%
OrbiMed Advisors, LLC
OrbiMed Advisors, LLC
5.52643%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.24434%
American Century Investment Management, Inc.
American Century Investment Management, Inc.
4.84508%
Champlain Investment Partners, LLC
Champlain Investment Partners, LLC
...

SI-BONE Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
18.20%
Yasunori Kaneko
Yasunori Kaneko
SEC ↗
18.20%
Skyline Venture Partners V, L.P.
Skyline Venture Partners V, L.P.
SEC ↗
18.20%
John G. Freund
John G. Freund
SEC ↗
18.02%
First Light Asset Management, LLC
First Light Asset Management, LLC
SEC ↗
9.49%
Brown Advisory Incorporated ("BAI")
Brown Advisory Incorporated ("BAI")
SEC ↗
9.44%
Brown Advisory LLC (BALLC)
Brown Advisory LLC (BALLC)
SEC ↗
8.37%
Montreux IV Associates, L.L.C.
Montreux IV Associates, L.L.C.
SEC ↗
8.37%
Montreux IV Associates IV, L.L.C.
Montreux IV Associates IV, L.L.C.
SEC ↗
8.37%
Montreux Equity Partners IV, L.P.
Montreux Equity Partners IV, L.P.
SEC ↗
8.37%
Daniel K. Turner, III
Daniel K. Turner, III
SEC ↗

SI-BONE Executives and Management Board

12 members · avg. age 60 · 25 % women

LF

Ms. Laura Francis (58)

Chief Executive Officer, Director · since 2015

7.09 M USD

Management

AR

Mr. Anthony Recupero (66)

President - Commercial Operations

2.56 M USD
AM

Mr. Anshul Maheshwari (45)

Chief Financial Officer

2.47 M USD
MP

Mr. Michael Pisetsky (47)

Secretary, Chief Business & Legal Affairs Officer

–

Board of Directors

DW

Mr. Daniel Wolf (41)

Independent Director

262,485.00 USD
TW

Mr. Thomas West (61)

Independent Director

254,571.00 USD
JD

Mr. Jeffrey Dunn (70)

Non-Executive Chairman of the Board · since 2008

199,712.00 USD
TD

Mr. Timothy Davis (55)

Lead Independent Director

184,712.00 USD
JH

Ms. Jeryl Hilleman (67)

Independent Director

179,712.00 USD
GH

Mr. Gregory Hinckley (78)

Independent Director

163,962.00 USD

Frequently asked questions about SI-BONE

The business model of SI-BONE Inc is focused on developing minimally invasive surgical solutions for patients suffering from sacroiliac (SI) joint disorders. The company specializes in the design and manufacturing of medical devices, including the iFuse Implant System. SI-BONE's innovative approach involves utilizing advanced technology and expertise to address the biomechanical causes of SI joint dysfunction. By providing effective treatment options, SI-BONE aims to improve patients' quality of life and restore their mobility. As a leader in the field, SI-BONE Inc continues to prioritize research, innovation, and collaboration with healthcare professionals in order to offer cutting-edge solutions for SI joint disorders.

SI-BONE Inc is primarily active in the healthcare industry, specifically specializing in the development and commercialization of innovative medical devices for patients suffering from musculoskeletal disorders. The company focuses on providing minimally invasive, cutting-edge solutions for the diagnosis and treatment of conditions related to the sacroiliac joint. With their groundbreaking technology and dedication to improving patient outcomes, SI-BONE Inc has positioned itself as a leader in the healthcare sector, offering effective solutions for individuals in need of long-term relief from debilitating pain and discomfort.

The main competitors of SI-BONE Inc in the market are Zimmer Biomet Holdings Inc, Medtronic PLC, and NuVasive Inc.

SI-BONE Inc is a leading medical device company specializing in minimally invasive solutions for the treatment of sacroiliac (SI) joint dysfunction. Founded in 2008, SI-BONE has emerged as a pioneer in this field, revolutionizing the way SI joint pain is diagnosed and treated. The company's flagship product is the iFuse Implant System, which provides a durable and minimally invasive option for patients suffering from SI joint dysfunction. Backed by extensive clinical research and a commitment to innovation, SI-BONE Inc has quickly gained recognition as a trusted provider of SI joint solutions, improving the quality of life for countless patients worldwide.

SI-BONE Inc has achieved several significant milestones in their history. One noteworthy accomplishment is the FDA clearance of their iFuse Implant System, a minimally invasive surgical solution for sacroiliac joint fusion. This clearance allowed SI-BONE Inc to offer their innovative treatment to patients suffering from SI joint dysfunction. Additionally, the company went public in 2018, marking another milestone in their growth. SI-BONE Inc's dedication to research and development has led to advancements in medical technology and improved patient outcomes. They continue to make strides in the field of SI joint fusion and are committed to providing effective solutions for patients.

SI-BONE Inc is primarily present in the United States and Europe.

SI-BONE Inc represents a commitment to improving patient lives through innovative medical solutions. Their corporate philosophy revolves around providing minimally invasive technologies for the diagnosis, treatment, and management of musculoskeletal disorders. The company actively focuses on advancing the field of sacroiliac joint dysfunction (SIJD) treatment with their FDA-cleared iFuse Implant System, offering a comprehensive solution for patients suffering from SIJD. SI-BONE Inc values patient-centric care, clinical research, collaboration with healthcare professionals, and continuous innovation to enhance patient outcomes. With their dedication to addressing unmet medical needs and improving quality of life, SI-BONE Inc has emerged as a trusted leader in the field of musculoskeletal healthcare.

Analysts currently set an average price target of 25.91 USD for the SI-BONE stock (median: 25.50 USD), implying +43.7 % versus the latest price. The consensus is based on 16 analyst ratings.

SI-BONE Analyst Price Targets 2026

16 analysts currently rate the SI-BONE stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SI-BONE to generate revenue of 231.62 M USD and earnings per share of -0.44 USD.

SI-BONE Analyst Price Targets 2026

Converted at the current exchange rate, the SI-BONE share trades at 15.64 EUR (18.03 USD).

The SI-BONE share (SIBN) is listed on 3 stock exchanges, including: NASDAQ (SIBN), Frankfurt (2K3.F), München (2K3.MU).

SI-BONE Inc is a medical company specialized in the development and marketing of innovative medical products in the field of spinal surgery. The company was founded in 2008 and is headquartered in Santa Clara, California. SI-BONE Inc specializes in the treatment of degenerative spinal diseases, particularly chronic lower back pain caused by Sacroiliac Joint Dysfunction. This condition affects millions of people worldwide and can lead to significant limitations in daily life. The business model of SI-BONE Inc is based on the development and marketing of innovative medical products aimed at improving the effectiveness and efficiency of Sacroiliac Joint Fusion (SI Fusion). Through the development of new technologies and applications, the company has introduced numerous products that support both minimally invasive and traditional surgical procedures. The flagship product of SI-BONE Inc is the iFuse Implant System, which is considered the only approved method for Sacroiliac Joint Fusion. The iFuse Implant is a small, triangular implant that is inserted into the SI Joint and provides permanent fixation. The implant is made of titanium, known for its strength and biocompatibility. In addition to the iFuse Implant System, SI-BONE Inc also offers a variety of training programs and support services for surgeons and medical professionals. The company has established a comprehensive network of clinics and medical centers to facilitate access to its products and services and raise awareness of the effectiveness of Sacroiliac Joint Fusion. SI-BONE Inc has also built a strong presence in the global market and works closely with international distributors to distribute its products worldwide. The company has branches in Europe, the Middle East, Africa, Asia, and Latin America to meet the needs of its global customers. The business model of SI-BONE Inc benefits both patients and surgeons and medical professionals. By providing innovative medical products and support services, the company contributes to improving patients' quality of life and avoiding potentially irreversible damage to the spine.

The expected revenue of SI-BONE is 231.62 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SI-BONE is -19.21 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SI-BONE is currently -40.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SI-BONE stock.

The price-to-sales ratio (P/S) of SI-BONE is currently 3.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SI-BONE stock.

The Eulerpool Quality Score for SI-BONE is 4/10.

The ISIN of SI-BONE is US8257041090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of SI-BONE is A2N7LY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of SI-BONE is SIBN. The ticker symbol is used to trade SI-BONE shares on the stock exchange.

SI-BONE paid dividends every year for the past 0 years.

SI-BONE is assigned to the 'Health' sector.

The dividends of SI-BONE are distributed in USD.

All fundamentals and in-depth analysis of SI-BONE

Our stock analysis for SI-BONE stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SI-BONE. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

SI-BONE Stock
SI-BONE Revenue→
SI-BONE Stock
SI-BONE Net Income→
SI-BONE Stock
SI-BONE P/E→
SI-BONE Stock
SI-BONE P/S→
SI-BONE Stock
SI-BONE EBIT→
SI-BONE Stock
SI-BONE Dividend→
SI-BONE Stock
SI-BONE Directors Dealings→
SI-BONE Stock
SI-BONE Stocks→
SI-BONE Stock
SI-BONE Market capitalization→
SI-BONE Stock
SI-BONE Debt→
SI-BONE Stock
SI-BONE Liabilities→
SI-BONE Stock
SI-BONE Equity→
SI-BONE Stock
SI-BONE AAQS→
SI-BONE Stock
SI-BONE Employees→
SI-BONE Stock
SI-BONE ROE→
SI-BONE Stock
SI-BONE ROA→
SI-BONE Stock
SI-BONE ROCE→
SI-BONE Stock
SI-BONE News→
SI-BONE Stock
SI-BONE Analyst Price Targets→

Health Stocks

Sichuan Biokin Pharmaceutical CoShuttle Pharmaceuticals HoldingsSichuan Gangtong Medical Equipment Group CoShukra PharmaceuticalsSichuan Goldstone Asia PharmaceuticalShree PacetronixSichuan Huiyu Pharmaceutical CoShree Ganesh RemediesSichuan Kelun Pharmaceutical CoShouyao Holdings CoSichuan Kelun-Biotech Biopharmaceutical CoShoulder InnovationsAll Stocks A–Z →